Drug profile · INN
rezafungin acetate
REZZAYO
rezafungin acetate (REZZAYO) is a candida inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — rezafungin acetate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
rezafungin acetate (REZZAYO) is a candida inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Candida inhibitor
Primary target: Candida
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is rezafungin acetate?
rezafungin acetate (REZZAYO) is a candida inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for rezafungin acetate?
REZZAYO is a marketed brand name for rezafungin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rezafungin acetate?
rezafungin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.